Bispecific Antibodies for Cancer Market will Register 6.44% YOY Growth in 2022 | 39% Growth to Originate from North America| 17,000+ Technavio Reports

Vendor Insights 

The bispecific antibodies for cancer market is fragmented and the vendors are deploying growth strategies such as price, quality, technology, brand identity, and distribution to compete in the market. Market vendors are focusing more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Companies are launching innovative products to stay up in the game. For instance, ABL Bio Inc. offers a wide range of bispecific antibodies for immuno-oncology and neurodegenerative diseases. The company offers bispecific antibodies such as ABL301, ABL001, and others. 

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• ABL Bio Inc.
• AFFIMED N.V.
• Akeso Inc.
• Amgen Inc.
• Aptevo Therapeutics Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Eli Lilly and Co.
• EPIMAB BIOTHERAPEUTICS INC.
• F. Hoffmann La Roche Ltd.
• F-STAR THERAPEUTICS INC.
• Glenmark Pharmaceuticals Ltd.
• Johnson and Johnson Inc.
• Mereo BioPharma Group Plc
• Merus N.V.
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• TG Therapeutics Inc.
• Xencor Inc.
• Y mAbs Therapeutics Inc.

Find additional highlights on the growth strategies adopted by vendors and their product offerings, Read Free Sample Report. 

Geographical Market Analysis 

North America was the largest revenue-generating regional segment of the market. 39% of the market's growth will originate from North America during the forecast period. The US is the key market for bispecific antibodies for cancer market in North America. Market growth in this region will be faster than the growth of the market in ROW. The availability of reimbursement schemes. will facilitate the bispecific antibodies for cancer market growth in North America over the forecast period.

Furthermore, countries such as Ireland and Hungary are expected to emerge as prominent economies for the market's growth during the forecast period. 

Know more about this market's geographical distribution along with the detailed analysis of the top regions. https://www.technavio.com/report/bispecific-antibodies-for-cancer-market-industry-analysis 

Key Segment Analysis

The CD19 or CD3 type segment held the largest market share in 2021. The segment will continue to account for the largest market share throughout the forecast period mainly due to the advantages of bispecific antibodies over monoclonal antibodies. They can redirect specific immune cells to the site of the tumor cells to enhance tumor killing, they can also potentially increase the binding specificity by interacting with two different cell-surface antigens instead of one antigen, besides being able to block two different pathways that exert unique pathogenesis simultaneously.

View FREE Sample: to know additional highlights and key points on various market segments and their impact in coming years. 

Key Market Driver & Challenge: 

The increasing prevalence of cancer is one of the key drivers supporting the bispecific antibodies for cancer market growth. Cancer causes significant economic setbacks as it is highly responsible for premature deaths. The rising cases of cancer have led to huge investments in the oncology segment. The increasing healthcare investment in developing countries is expected to boost the growth of the bispecific antibodies for cancer market during the forecast period. The rising investments in cancer treatment will directly lead to a higher demand for supportive care therapy drugs. Thus, the increasing prevalence of cancer worldwide will drive the market's growth during the forecast period.

The high cost of drugs is one of the factors hindering the bispecific antibodies for cancer market growth. The majority of cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach. Patients with a history of cancer were more likely to stop their treatment due to the high cost of drugs used in the treatment of various cancers. Therefore, the high cost of the drug poses a challenge to the growth of the market.

Download free sample for highlights on market Drivers & Challenges affecting the bispecific antibodies for cancer market. 

Customize Your Report 

Don't miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.  

We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now! 

Related Reports: 

Cancer Monoclonal Antibodies Market by Type and Geography - Forecast and Analysis 2021-2025

Biosimilar Monoclonal Antibodies (mAbs) Market by Application and Geography- Forecast and Analysis 2021-2025

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 CD19 or CD3 - Market size and forecast 2021-2026
• Exhibit 28: Chart on CD19 or CD3 - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on CD19 or CD3 - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on CD19 or CD3 - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on CD19 or CD3 - Year-over-year growth 2021-2026 (%)

• 5.4 CD30 or CD16A - Market size and forecast 2021-2026
• Exhibit 32: Chart on CD30 or CD16A - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on CD30 or CD16A - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on CD30 or CD16A - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on CD30 or CD16A - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Ireland - Market size and forecast 2021-2026
• Exhibit 62: Chart on Ireland - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Ireland - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Ireland - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Ireland - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Hungary - Market size and forecast 2021-2026
• Exhibit 70: Chart on Hungary - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Hungary - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Hungary - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Hungary - Year-over-year growth 2021-2026 (%)

• 7.11 India - Market size and forecast 2021-2026
• Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 ABL Bio Inc.
• Exhibit 85: ABL Bio Inc. - Overview
• Exhibit 86: ABL Bio Inc. - Product / Service
• Exhibit 87: ABL Bio Inc. - Key offerings

• 10.4 Amgen Inc.
• Exhibit 88: Amgen Inc. - Overview
• Exhibit 89: Amgen Inc. - Product / Service
• Exhibit 90: Amgen Inc. - Key offerings

• 10.5 Astellas Pharma Inc.
• Exhibit 91: Astellas Pharma Inc. - Overview
• Exhibit 92: Astellas Pharma Inc. - Product / Service
• Exhibit 93: Astellas Pharma Inc. - Key news
• Exhibit 94: Astellas Pharma Inc. - Key offerings

• 10.6 Eli Lilly and Co.
• Exhibit 95: Eli Lilly and Co. - Overview
• Exhibit 96: Eli Lilly and Co. - Business segments
• Exhibit 97: Eli Lilly and Co. - Key offerings
• Exhibit 98: Eli Lilly and Co. - Segment focus

• 10.7 F. Hoffmann La Roche Ltd.
• Exhibit 99: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 100: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 101: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 102: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 103: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Johnson and Johnson Inc.
• Exhibit 104: Johnson and Johnson Inc. - Overview
• Exhibit 105: Johnson and Johnson Inc. - Business segments
• Exhibit 106: Johnson and Johnson Inc. - Key news
• Exhibit 107: Johnson and Johnson Inc. - Key offerings
• Exhibit 108: Johnson and Johnson Inc. - Segment focus

• 10.9 Merus N.V.
• Exhibit 109: Merus N.V. - Overview
• Exhibit 110: Merus N.V. - Key offerings

• 10.10 Pfizer Inc.
• Exhibit 111: Pfizer Inc. - Overview
• Exhibit 112: Pfizer Inc. - Product / Service
• Exhibit 113: Pfizer Inc. - Key news
• Exhibit 114: Pfizer Inc. - Key offerings

• 10.11 Regeneron Pharmaceuticals Inc.
• Exhibit 115: Regeneron Pharmaceuticals Inc. - Overview
• Exhibit 116: Regeneron Pharmaceuticals Inc. - Product / Service
• Exhibit 117: Regeneron Pharmaceuticals Inc. - Key offerings

• 10.12 TG Therapeutics Inc.
• Exhibit 118: TG Therapeutics Inc. - Overview
• Exhibit 119: TG Therapeutics Inc. - Product / Service
• Exhibit 120: TG Therapeutics Inc. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 121: Inclusions checklist
• Exhibit 122: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 123: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 124: Research methodology
• Exhibit 125: Validation techniques employed for market sizing
• Exhibit 126: Information sources

• 11.5 List of abbreviations
• Exhibit 127: List of abbreviations

About Us: 

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. 

Contact 
Technavio Research 
Jesse Maida 
Media & Marketing Executive 
US: +1 844 364 1100 
UK: +44 203 893 3200 
Email: [email protected] 
Website: www.technavio.com

SOURCE Technavio